Home » Stocks » ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR)

Stock Price: $83.78 USD 4.12 (5.17%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $83.72 -0.06 (-0.07%) Mar 1, 6:04 PM
Market Cap 8.67B
Revenue (ttm) 79.84M
Net Income (ttm) -102.61M
Shares Out 102.76M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $83.78
Previous Close $79.66
Change ($) 4.12
Change (%) 5.17%
Day's Open 81.14
Day's Range 81.06 - 84.45
Day's Volume 567,615
52-Week Range 19.51 - 92.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals...

Business Wire - 1 month ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia

Business Wire - 1 month ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021

Seeking Alpha - 2 months ago

ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their...

InvestorPlace - 2 months ago

Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on Inve...

Other stocks mentioned: DD, IBM, INTC, TMO, ONTO, VECO
Business Wire - 2 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited

Benzinga - 3 months ago

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluri...

Other stocks mentioned: ADXS, ALNY
Seeking Alpha - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36% over the...

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3

Business Wire - 3 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings

The Motley Fool - 4 months ago

These biotechs are fueling up for massive market launches.

Other stocks mentioned: CRSP
Forbes - 4 months ago

Despite a 3x growth since the March 18 lows of this year, at the current price of around $60 per share we believe Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interf...

Forbes - 4 months ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: ALKS, NBIX, ACAD, BMRN, IONS
The Motley Fool - 4 months ago

Vertex's losses are Arrowhead's gains.

Seeking Alpha - 4 months ago

Arrowhead Pharmaceuticals establishes deal with Takeda for the use of ARO-AAT in a deal worth up to $1.04 billion.

Seeking Alpha - 4 months ago

Arrowhead's New Deal With Takeda Strengthens The Company's Value Proposition

Other stocks mentioned: TAK
Business Wire - 5 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference

Business Wire - 5 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports inducement grants

InvestorPlace - 5 months ago

Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher. The post Arrowhead Pharmaceuticals News: Why ARWR Stock I...

Investors Business Daily - 5 months ago

Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumpe...

The Motley Fool - 5 months ago

The company reported positive interim data from a clinical trial.

24/7 Wall Street - 5 months ago

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT.

Seeking Alpha - 5 months ago

Arrowhead Pharmaceuticals Is A Smart Long-Term Opportunity

Business Wire - 5 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead appoints veteran pharmaceutical industry executive Oye Olukotun, M.D.

Business Wire - 5 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020

Business Wire - 6 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Janssen present Phase clinical data on hepatitis B treatment JNJ-3989 at EASL International Liver Congress 2020

Investors Business Daily - 6 months ago

Arrowhead Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Arrowhead Pharma Shows Improved Relative Price Strength ap...

Business Wire - 6 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at August 2020 conferences

Business Wire - 6 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma

Seeking Alpha - 6 months ago

BioBoyScout recently raised his price target on Arrowhead Pharmaceuticals to $107.

Business Wire - 6 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

Seeking Alpha - 6 months ago

Most Medical Development & Treatment companies tend not to be involved in the Covid-19 virus vaccine race.

Seeking Alpha - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2020 Results - Earnings Call Transcript

Business Wire - 6 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal Q3 2020 earnings results and hosts conference call

Business Wire - 7 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA

Business Wire - 7 months ago

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals and Marcus Mall MD host a webinar on ARO-ENaC for the treatment of cystic fibrosis

Seeking Alpha - 7 months ago

Arrowhead Pharmaceuticals: Updates To Thesis, RNAi Pioneer Continues To Move Key Programs Closer To Inflection Points

The Motley Fool - 7 months ago

The RNAi treatment developer is clawing its way back after a rough start to 2020.

Seeking Alpha - 8 months ago

Arrowhead Pharmaceuticals Is A Long-Term Investment To Consider

Seeking Alpha - 8 months ago

Quietly Adding More Shares Of Arrowhead Pharmaceuticals

The Motley Fool - 8 months ago

Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?

Other stocks mentioned: JNJ
The Motley Fool - 9 months ago

The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.

The Motley Fool - 9 months ago

A leading company in the field of gene silencing is on track to develop several breakthrough therapies.

About ARWR

Arrowhead Pharmaceuticals develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical t... [Read more...]

Industry
Biotechnology
IPO Date
Jun 16, 1993
CEO
Christopher Anzalone
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
ARWR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 92.42, which is an increase of 10.31% from the latest price.

Price Target
$92.42
(10.31% upside)
Analyst Consensus: Buy